Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates
π Cencora reported Q4 earnings of $4.66 per share, beating the consensus estimate of $4.56 by 2.19%.
π° Quarterly revenues reached $88.35 billion, surpassing analyst expectations by 0.22%.
π The company has beaten EPS estimates in three out of its last four quarters.
π Shares have underperformed the S&P 500 this year with a gain of only 0.8% versus the index's 10.6% rise.
π The stock maintains a Zacks Rank #2 (Buy) due to favorable earnings estimate revisions.
π Year-over-year revenue growth was approximately 5.5%, rising from $83.73 billion to $88.35 billion.
Bullish Signals
- Cencora beat quarterly EPS estimates by 2.19% with earnings of $4.66 per share versus the consensus of $4.56.
- The company has a strong track record of beating earnings expectations, surpassing consensus EPS in three of its last four quarters.
- Revenue growth remains solid with quarterly sales reaching $88.35 billion, up from $83.73 billion year-over-year.
Risk Factors
- Cencora shares have significantly underperformed the broader market this year, gaining only 0.8% compared to the S&P 500's 10.6% gain.
- The company topped revenue estimates just once in the last four quarters, indicating less consistent revenue performance than earnings.
Full Analysis
Cencora (COR) reported quarterly earnings of $4.66 per share, surpassing the consensus estimate of $4.56 and representing a 2.19% surprise. This figure compares favorably to the prior year's adjusted earnings of $3.84 per share. The company has exceeded EPS estimates in three of its last four quarters, demonstrating consistent performance relative to analyst expectations.
The prescription drug distributor posted quarterly revenues of $88.35 billion for the period ended September 2026, beating the consensus estimate by 0.22%. While revenue beat was modest compared to the strong earnings surprise, year-over-year revenue growth remains robust at approximately 5.5% compared to $83.73 billion a year ago. Cencora has topped revenue estimates only once in the last four quarters.
Following the earnings release, Cencora shares have gained about 0.8% since the beginning of the year, though they continue to underperform the S&P 500's 10.6% gain for the same period. The stock currently holds a Zacks Rank #2 (Buy) based on favorable estimate revisions ahead of the report. Investors are watching management commentary and future earnings outlooks to determine if the stock can regain its market momentum.